Core Points - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock about the December 15, 2025 lead plaintiff deadline for a class action lawsuit [1][3] - Investors who purchased shares during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The complaint alleges that during the Class Period, defendants made false and misleading statements regarding the efficacy of SLK compared to traditional monoclonal antibodies, specifically concerning the molecular targets and clinical benefits [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information provided by the defendants [5] Legal Process - To join the class action, investors can submit a form or contact the law firm directly for more information [3][6] - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7]

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and its senior executives for potential violations of federal securities laws, following disappointing results from its Phase 3 VELA trials for sonelokimab [1][2][3]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, captioned Peters v. MoonLake Immunotherapeutics, et al., No. 1:25-cv-08612 [2]. - Investors have until December 15, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background - MoonLake is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases, specifically targeting moderate to severe hidradenitis suppurativa with its investigational drug sonelokimab [3]. Group 3: Clinical Trials and Allegations - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients, suggesting a competitive advantage for sonelokimab [4]. - Allegations state that the clinical data and Nanobody structure did not provide a superior clinical benefit compared to competitors, raising doubts about the drug's regulatory approval and commercial viability [5]. Group 4: Stock Performance - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 per share to $6.24 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of MoonLake Immunotherapeutics during the specified Class Period of the upcoming lead plaintiff deadline on December 15, 2025 [1] Group 1: Class Action Details - Investors who bought MoonLake common stock between March 10, 2024, and September 29, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - To participate in the class action, investors can visit the provided link or contact the law firm for more information [3][6] - A lead plaintiff must file a motion with the Court by December 15, 2025, to represent other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions [4] - The firm has achieved significant settlements, including the largest securities class action settlement against a Chinese company, and has consistently ranked highly in securities class action settlements since 2013 [4] - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering funds for clients [4] Group 3: Case Allegations - The complaint alleges that during the Class Period, defendants made false or misleading statements regarding the efficacy of their product SLK compared to traditional monoclonal antibodies [5] - Specific claims include that SLK and BIMZELX target the same inflammatory cytokines, and that SLK's unique structure does not provide superior clinical benefits [5] - The lawsuit claims that when the true information became public, investors suffered damages due to the misleading statements [5]

Core Viewpoint - Rosen Law Firm is encouraging investors of MoonLake Immunotherapeutics who incurred losses exceeding $100,000 during the specified class period to seek legal counsel before the December 15, 2025 deadline for lead plaintiff applications [1][2]. Group 1: Class Action Details - The class period for the MoonLake Immunotherapeutics securities class action is from March 10, 2024, to September 29, 2025 [1]. - Investors who purchased common stock during this period may be eligible for compensation without any upfront fees through a contingency fee arrangement [2]. - To participate in the class action, investors must apply by December 15, 2025, to serve as lead plaintiff, representing other class members [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant settlements for investors [4]. - The firm has been recognized for its achievements, including being ranked No. 1 for securities class action settlements in 2017 and recovering over $438 million for investors in 2019 [4]. Group 3: Case Allegations - The complaint alleges that during the class period, MoonLake Immunotherapeutics made false or misleading statements regarding the efficacy of its product SLK compared to traditional monoclonal antibodies, specifically BIMZELX [5]. - Key points of contention include claims about the molecular targets and clinical benefits of SLK, which were allegedly overstated, leading to investor damages when the truth was revealed [5].

Core Viewpoint - MoonLake Immunotherapeutics has faced a significant decline in share price, dropping nearly 90% in one day due to disappointing Phase 3 trial results for its drug candidate sonelokimab (SLK) [1][5]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing SLK, which is intended to treat moderate to severe hidradenitis suppurativa (HS), a chronic inflammatory skin disease [3]. Legal Issues - A securities fraud class action lawsuit has been filed against MoonLake in the U.S. District Court for the Southern District of New York, alleging that the company and certain executives made materially false and misleading statements regarding SLK's clinical prospects [2][4]. - The lawsuit claims that MoonLake exaggerated SLK's benefits over competitors, particularly in relation to its unique "Nanobody" structure, which was presented as a major competitive advantage [4][6]. Trial Results - The VELA Phase 3 trials, particularly VELA-2, did not meet their primary endpoint, leading to a significant drop in stock price from $61.99 to $6.24, a decrease of $55.75 per share [5]. - Analysts noted that the efficacy results from the successful trial were substantially lower than those achieved by the competitor drug BIMZELX, which shares the same molecular targets [4][6]. Investor Impact - The decline in stock price has prompted Hagens Berman, a plaintiffs' rights firm, to investigate claims of misleading information that may have artificially inflated the stock price during the class period from March 10, 2024, to September 29, 2025 [2][6].

Core Viewpoint - aTyr Pharma, Inc. is facing intensified financial and legal pressures following disappointing third-quarter results that missed Wall Street estimates, alongside ongoing securities class action litigation related to misleading information about its drug Efzofitimod [1][5]. Financial Performance - aTyr reported a GAAP EPS loss of -$0.26 for Q3, missing analyst consensus estimates by $0.08 [3]. - The company's revenues were reported at $190,000, indicating a heavy reliance on its clinical pipeline rather than commercial sales [3]. Clinical Developments - Despite the disappointing results from the Phase 3 EFZO-FIT study, aTyr plans to meet with the U.S. FDA in Q1 2026 to discuss the study results and the future of Efzofitimod in treating pulmonary sarcoidosis [4]. - The EFZO-FIT study did not meet its primary endpoint, leading to a significant market reaction with the stock price dropping over 83% in one day, from $6.03 to $1.02 [6]. Legal Issues - The ongoing securities class action litigation alleges that aTyr and its executives provided materially false and misleading information regarding Efzofitimod's efficacy [5]. - The class action period has been expanded to include investors who acquired shares between November 7, 2024, and September 12, 2025, with claims that the company concealed deficiencies in the drug's performance [7]. - Hagens Berman is investigating whether aTyr misled investors about its data and trial design while promoting Efzofitimod's market potential [8].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding the launch of its Inspire V device for obstructive sleep apnea, which resulted in a significant decline in stock price [1][5]. Company Overview - Inspire Medical Systems, Inc. specializes in implantable neurostimulation technology aimed at improving respiration during sleep [3]. Legal Proceedings - The lawsuit, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., targets the company and its executives, representing investors who acquired stock between August 6, 2024, and August 4, 2025 [2][6]. - The lead plaintiff deadline for the lawsuit is set for January 5, 2026 [2]. Allegations - The complaint alleges that the company misrepresented the transition to the Inspire V device as seamless, while in reality, it faced significant operational challenges [3][6]. - Key allegations include poor market demand, incomplete readiness for the launch, and undisclosed logistical issues that hindered the rollout of the Inspire V device [8]. Market Reaction - On August 4, 2025, Inspire Medical publicly acknowledged that the launch of the Inspire V device was facing an "elongated timeframe," leading to a drastic reduction in 2025 earnings guidance by over 80% [4][5]. - Following this announcement, the company's stock price plummeted by over 32% on heavy trading volume [5]. Investigation Focus - Hagens Berman is investigating potential misstatements or omissions related to the Inspire V device launch and its financial implications [7]. - The investigation is particularly focused on whether management was aware of critical operational flaws, such as billing code delays and training deficiencies, prior to the public disclosure [9].

Core Viewpoint - A lawsuit has been filed against MoonLake Immunotherapeutics and certain senior executives for potential violations of federal securities laws, with a deadline for investors to act by December 15, 2025 [1][3]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases [4]. - The company conducted Phase 3 VELA trials for sonelokimab (SLK), aimed at treating moderate to severe hidradenitis suppurativa [4]. Allegations and Clinical Data - MoonLake claimed that its "strong clinical data" from the Phase 2 MIRA trial indicated superior clinical responses for patients and differentiation from competitors [5]. - Allegations suggest that the clinical data and Nanobody structure did not provide a superior clinical benefit, raising doubts about the drug's regulatory approval and commercial viability [6]. Stock Performance and Impact - Following the announcement of disappointing results from the VELA Phase 3 trials on September 28, 2025, MoonLake's stock price plummeted nearly 90%, from $61.99 to $6.24 per share [7].

Core Viewpoint - MoonLake Immunotherapeutics is facing a class action lawsuit due to allegations of misleading investors about the efficacy of its drug candidate SLK, particularly in comparison to the FDA-approved drug BIMZELX [1][3]. Company Overview - MoonLake Immunotherapeutics (MLTX) is a Swiss clinical-stage biotechnology company focused on inflammatory diseases driven by interleukin-17 (IL-17), with a particular emphasis on dermatology and rheumatology [1]. Class Action Details - The class period for the lawsuit is defined as March 10, 2024, to September 29, 2025 [1]. - The lawsuit was filed on behalf of all investors who purchased or acquired MoonLake's common stock during this period [1]. Allegations - The complaint outlines several key allegations: - SLK and BIMZELX share the same molecular targets (IL-17A and IL-17F) [3]. - SLK's Nanobody structure does not provide a superior clinical benefit over BIMZELX's monoclonal structure [3]. - The supposed increased tissue penetration of SLK does not translate to clinical efficacy [3]. - Defendants lacked a reasonable basis for their positive statements regarding SLK's superiority [3]. Stock Price Impact - Following the announcement of the week-16 results from the Phase 3 VELA program on September 28, 2025, which showed SLK's failure to demonstrate competitive efficacy relative to BIMZELX, MoonLake's stock price dropped significantly [4]. - The stock price fell by $55.75 per share, or 89.9%, closing at $6.24 on September 29, 2025 [4].

Core Viewpoint - Investors in Perrigo Company plc have the opportunity to lead a securities fraud class action lawsuit due to undisclosed operational issues and financial misstatements related to the company's infant formula business [1][2]. Summary by Sections Lawsuit Details - The lawsuit alleges that from February 27, 2023, to November 4, 2025, Perrigo failed to disclose significant underinvestment in the acquired infant formula business from Nestlé, which affected maintenance and operational improvements [2]. - It is claimed that Perrigo needed to incur substantial capital and operational expenditures beyond previously stated cost estimates to address issues in the infant formula business [2]. - The complaint highlights significant manufacturing deficiencies in the infant formula facility, leading to overstated financial results, including earnings and cash flow [2]. - As a result of these issues, the positive statements made by Perrigo regarding its business operations and prospects were materially misleading [2]. Participation Information - Investors who suffered losses related to Perrigo are encouraged to participate in the ongoing securities fraud lawsuit, with a lead plaintiff deadline set for January 16, 2026 [2][3]. - Interested parties can contact the Law Offices of Frank R. Cruz for more information or to participate in the lawsuit [3][4].